Κατεύθυνση Αλγολογία: Αντιμετώπιση του πόνου, διάγνωση και θεραπεία. Φαρμακευτικές, παρεμβατικές και άλλες τεχνικές
Library of the School of Health Sciences

2020-07-16

2020

Georgakopoulos Panagiotis

Στάικου Χρυσούλα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Επιβλέπουσα
Παπαδόπουλος Γεώργιος, Καθηγητής, Τμήμα Ιατρικής, Πανεπιστήμιο Ιωαννίνων
Σιαφάκα Ιωάννα, Καθηγήτρια, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών

Η αποτελεσματικότητα της πρεγκαμπαλίνης στην αντιμετώπιση του περιφερικού νευροπαθητικού πόνου. Ανασκόπηση

Greek

Efficacy of pregabalin in the treatment of peripheral neuropathic pain. A systematic review

Background: Chronic peripheral neuropathic pain is a complex clinical entity with various underlying etiology. Every lesion or disease affecting the peripheral somatosensory system can cause peripheral neuropathic pain, with diabetic neuropathy, postherpetic neuralgia, and cancer-related pain, being the most common causes. Due to the complex pathophysiology and the variability of the underlying cause, effective treatment of peripheral neuropathic pain consists of a major clinical challenge. Administration of pregabalin for the treatment of peripheral neuropathic pain has been approved for the last 15 years, with variable efficacy.

Aim: The present paper is a systematic review aiming to evaluate the efficacy of pregabalin in chronic peripheral neuropathic pain conditions.

Methodology: After a thorough search of MEDLINE, Phase 3 clinical trials, with at least 25 participants and a minimum duration of 2 weeks, were eligible to be included in the present paper.

Results: Pregabalin shows various efficacy against chronic peripheral neuropathic pain, depending on the underlying cause. The use of pregabalin against diabetic neuropathy and postherpetic neuralgia is well documented and supported by a large amount of evidence, while pregabalin shows no efficacy against HIV-related neuropathic pain. In addition, there are not enough data about cancer-related neuropathic pain and lumbar radiculopathy with neuropathic pain. In most studies, pregabalin showed a favorable safety profile, with mild to moderate adverse effects, predominantly dizziness, somnolence, and peripheral edema.

Conclusions: Pregabalin has clinically significant efficacy against chronic peripheral neuropathic pain in about 50% of patients receiving it while the loss of response can be observed through time. Considering the complex clinical entity of peripheral neuropathic pain and the well-documented efficacy of pregabalin against it, future studies should aim to investigate the optimal combination and timepoint of therapeutic interventions to achieve maximum pain relief.

Health Sciences

Pregabalin, Peripheral neuropathic pain, Treatment, Efficacy, Systematic review

No

0

Yes

138

147

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2919641